Sanofi Q2 2013 - Interview with CEO Chris Viehbacher

Before you go, we thought you'd like these...
Before you go close icon

Sanofi Q2 2013 - Interview with CEO Chris Viehbacher

PARIS--(BUSINESS WIRE)-- Sanofi, a global and diversified healthcare leader, reports results for the second quarter of 2013. CEO Chris Viehbacher comments on Q2 results and outlook.

Watch the video interview here:


http://www.eurobusinessmedia.com/Sanofi-Q2-2013-Interview-with-CEO-Chris-Viehbacher?utm_source=ceo-direct&utm_medium=bw

Topics covered in the interview include:

- Q2 2013 Results

- FY 2013 Guidance

- Capital Allocation

- Diabetes

- Vaccines

- Genzyme

- Animal Health

- Emerging Markets

- R&D Pipeline

- Recent appointments

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYS: SNY) .

Company website: www.sanofi.com



Sanofi
Investor Relations:
Sébastien Martel, +33 1 53 77 45 45
IR@sanofi.com
or
Media Relations:
+33 1 53 77 45 02
MR@sanofi.com

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:

The article Sanofi Q2 2013 - Interview with CEO Chris Viehbacher originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners